董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kevin O'Boyle | 男 | Director | 69 | 未披露 | 未持股 | 2025-07-07 |
| Quentin S. Blackford | 男 | Director, President and Chief Executive Officer | 46 | 924.13万美元 | 未持股 | 2025-07-07 |
| Cathleen Noel Bairey Merz | 女 | Independent Director | 69 | 19.51万美元 | 未持股 | 2025-07-07 |
| Karen Ling | 女 | Independent Director | 61 | 34.05万美元 | 未持股 | 2025-07-07 |
| Brian B. Yoor | -- | Independent Director | -- | 未披露 | 未持股 | 2025-07-07 |
| Abhijit Y. Talwalkar | 男 | Chairman of the Board | 61 | 25.28万美元 | 未持股 | 2025-07-07 |
| Bruce G. Bodaken | 男 | Independent Director | 73 | 20.53万美元 | 未持股 | 2025-07-07 |
| Karen McGinnis | 女 | Director | 58 | 未披露 | 未持股 | 2025-07-07 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Quentin S. Blackford | 男 | Director, President and Chief Executive Officer | 46 | 924.13万美元 | 未持股 | 2025-07-07 |
| Daniel G. Wilson | 男 | Chief Financial Officer | 43 | 353.94万美元 | 未持股 | 2025-07-07 |
| Marc Rosenbaum | -- | Senior Vice President, Finance and Chief Accounting Officer | -- | 未披露 | 未持股 | 2025-07-07 |
| Sumi Shrishrimal | -- | Executive Vice President and Chief Risk Officer | -- | 未披露 | 未持股 | 2025-07-07 |
| Patrick M. Murphy | -- | Chief Business Officer and Chief Legal Officer | -- | 未披露 | 未持股 | 2025-07-07 |
| Chad Patterson | -- | Chief Commercial Officer | -- | 未披露 | 未持股 | 2025-07-07 |
| Minang Turakhia | -- | Chief Medical Officer, Chief Scientific Officer and Executive Vice President, Product Innovation | -- | 未披露 | 未持股 | 2025-07-07 |
| Mervin Smith | -- | Executive Vice President, Business Operations | -- | 未披露 | 未持股 | 2025-07-07 |
董事简历
中英对照 | 中文 | 英文- Kevin O'Boyle
-
Kevin O'Boyle，他是公司的董事（2014年7月以来）。从2010年12月到2011年7月，他曾担任Advanced BioHealing公司的高级副总裁兼首席财务官，直到公司被Shire公司收购。从2003年初到2009年9月，他曾担任NuVasive公司的首席财务官。他目前担任GenMark Diagnostics公司、Durata Therapeutics公司、Tornier公司、Zeltiq Aesthetics公司的董事。他持有Rochester Institute of Technology的会计学士学位，以及加州大学洛杉矶分校安德森商学院（UCLA Anderson School of Management）的执行管理项目。
Kevin O'Boyle,has served as a member of Board of Directors since September 2024. Mr. O'Boyle has over 20 years of executive management experience in the medical device industry. Mr. O'Boyle previously served on the boards of Nevro, Inc., from March 2019 until it was acquired in April 2025, where he was the chair of the audit committee; Sientra, Inc., from May 2014 to June 2023, where he was the chair of the audit committee and a member of the nominating and corporate governance committee; GenMark Diagnostics, Inc. from, February 2010 until it was acquired in April 2021, where he was chairman of the board and the chair of the audit committee, and Wright Medical Group N.V., from November 2015 until it was acquired in November 2020, where he was the chair of the audit committee. Mr. O'Boyle received a B.S. in accounting from the Rochester Institute of Technology and completed the Executive Program at the University of California Los Angeles, Anderson School of Management. - Kevin O'Boyle，他是公司的董事（2014年7月以来）。从2010年12月到2011年7月，他曾担任Advanced BioHealing公司的高级副总裁兼首席财务官，直到公司被Shire公司收购。从2003年初到2009年9月，他曾担任NuVasive公司的首席财务官。他目前担任GenMark Diagnostics公司、Durata Therapeutics公司、Tornier公司、Zeltiq Aesthetics公司的董事。他持有Rochester Institute of Technology的会计学士学位，以及加州大学洛杉矶分校安德森商学院（UCLA Anderson School of Management）的执行管理项目。
- Kevin O'Boyle,has served as a member of Board of Directors since September 2024. Mr. O'Boyle has over 20 years of executive management experience in the medical device industry. Mr. O'Boyle previously served on the boards of Nevro, Inc., from March 2019 until it was acquired in April 2025, where he was the chair of the audit committee; Sientra, Inc., from May 2014 to June 2023, where he was the chair of the audit committee and a member of the nominating and corporate governance committee; GenMark Diagnostics, Inc. from, February 2010 until it was acquired in April 2021, where he was chairman of the board and the chair of the audit committee, and Wright Medical Group N.V., from November 2015 until it was acquired in November 2020, where he was the chair of the audit committee. Mr. O'Boyle received a B.S. in accounting from the Rochester Institute of Technology and completed the Executive Program at the University of California Los Angeles, Anderson School of Management.
- Quentin S. Blackford
-
Quentin S. Blackford担任Dexcom, Inc.的首席运营官，截至2021年3月19日，Blackford先生承担Dexcom, Inc.的战略和企业发展职能，以及Dexcom, Inc.的财务和运营职能。Blackford先生于2017年9月加入Dexcom，担任Dexcom, Inc.的首席财务官，并于2019年10月1日晋升为首席运营官和首席财务官。加入Dexcom之前，他曾担任NuVasive的执行副总裁兼首席财务官（2014年8月至2017年8月）。2016年8月，Blackford先生被提升为执行副总裁、首席财务官、战略和企业诚信主管，负责领导财务、战略、企业发展、合规、质量和监管。从2012年7月到2014年8月，他担任NuVasive的财务和投资者关系执行副总裁，从2011年1月到2012年6月，他担任财务副总裁。他在几次收购中发挥了重要作用，以建立NuVasive的产品组合，进入新的产品领域，以及地理扩张。加入NuVasive之前，Blackford先生曾任职Zimmer Holdings, Inc.，在那里他领导该组织的全球财务规划和分析小组，此外还担任财务总监和牙科部门的财务总监。Blackford先生自2017年10月起担任Alphatec Holdings, Inc.和Axogen, Inc.的董事会独立成员（2019年5月以来）。Blackford先生在Grace College获得会计和工商管理双学士学位后获得了他的注册会计师执照。
Quentin S. Blackford serves as Dexcom, Inc.'s Chief Operating Officer and as of March 19 2021 Mr. Blackford has assumed responsibility for Dexcom, Inc.'s strategy and corporate development functions, in addition to Dexcom, Inc.'s finance and operations functions. Mr. Blackford joined Dexcom in September 2017 as Dexcom, Inc.'s Chief Financial Officer and was also promoted to Chief Operating Officer and Chief Financial Officer, effective October 1 2019. Prior to Dexcom, Mr. Blackford served as NuVasive's Executive Vice President, Chief Financial Officer from August 2014 to August 2017. In August 2016 Mr. Blackford was promoted to the role of Executive Vice President, Chief Financial Officer, Head of Strategy and Corporate Integrity in which role Mr. Blackford was responsible for leading Finance, Strategy, Corporate Development, Compliance, Quality and Regulatory. From July 2012 to August 2014 Mr. Blackford served as NuVasive's Executive Vice President of Finance and Investor Relations, and from January 2011 to June 2012 he served as Vice President, Finance. He was instrumental in several acquisitions to build upon NuVasive's portfolio of products and entry into new product segments, as well as geographic expansion. Prior to his roles at NuVasive, Mr. Blackford worked at Zimmer Holdings, Inc. where he led the organization's Global Financial Planning & Analysis group, in addition to serving as Director of Finance and Controller of the Dental Division. Mr. Blackford has served as an independent member of the Board of Directors of Alphatec Holdings, Inc. since October 2017 and Axogen, Inc. since May 2019. Mr. Blackford obtained his Certified Public Accounting license currently inactive after receiving dual Bachelor of Science degrees in Accounting and Business Administration from Grace College. - Quentin S. Blackford担任Dexcom, Inc.的首席运营官，截至2021年3月19日，Blackford先生承担Dexcom, Inc.的战略和企业发展职能，以及Dexcom, Inc.的财务和运营职能。Blackford先生于2017年9月加入Dexcom，担任Dexcom, Inc.的首席财务官，并于2019年10月1日晋升为首席运营官和首席财务官。加入Dexcom之前，他曾担任NuVasive的执行副总裁兼首席财务官（2014年8月至2017年8月）。2016年8月，Blackford先生被提升为执行副总裁、首席财务官、战略和企业诚信主管，负责领导财务、战略、企业发展、合规、质量和监管。从2012年7月到2014年8月，他担任NuVasive的财务和投资者关系执行副总裁，从2011年1月到2012年6月，他担任财务副总裁。他在几次收购中发挥了重要作用，以建立NuVasive的产品组合，进入新的产品领域，以及地理扩张。加入NuVasive之前，Blackford先生曾任职Zimmer Holdings, Inc.，在那里他领导该组织的全球财务规划和分析小组，此外还担任财务总监和牙科部门的财务总监。Blackford先生自2017年10月起担任Alphatec Holdings, Inc.和Axogen, Inc.的董事会独立成员（2019年5月以来）。Blackford先生在Grace College获得会计和工商管理双学士学位后获得了他的注册会计师执照。
- Quentin S. Blackford serves as Dexcom, Inc.'s Chief Operating Officer and as of March 19 2021 Mr. Blackford has assumed responsibility for Dexcom, Inc.'s strategy and corporate development functions, in addition to Dexcom, Inc.'s finance and operations functions. Mr. Blackford joined Dexcom in September 2017 as Dexcom, Inc.'s Chief Financial Officer and was also promoted to Chief Operating Officer and Chief Financial Officer, effective October 1 2019. Prior to Dexcom, Mr. Blackford served as NuVasive's Executive Vice President, Chief Financial Officer from August 2014 to August 2017. In August 2016 Mr. Blackford was promoted to the role of Executive Vice President, Chief Financial Officer, Head of Strategy and Corporate Integrity in which role Mr. Blackford was responsible for leading Finance, Strategy, Corporate Development, Compliance, Quality and Regulatory. From July 2012 to August 2014 Mr. Blackford served as NuVasive's Executive Vice President of Finance and Investor Relations, and from January 2011 to June 2012 he served as Vice President, Finance. He was instrumental in several acquisitions to build upon NuVasive's portfolio of products and entry into new product segments, as well as geographic expansion. Prior to his roles at NuVasive, Mr. Blackford worked at Zimmer Holdings, Inc. where he led the organization's Global Financial Planning & Analysis group, in addition to serving as Director of Finance and Controller of the Dental Division. Mr. Blackford has served as an independent member of the Board of Directors of Alphatec Holdings, Inc. since October 2017 and Axogen, Inc. since May 2019. Mr. Blackford obtained his Certified Public Accounting license currently inactive after receiving dual Bachelor of Science degrees in Accounting and Business Administration from Grace College.
- Cathleen Noel Bairey Merz
-
Cathleen Noel Bairey Merz自2018年4月起担任Irhythm Technologies，Inc.董事会成员。Bairey Merz博士自1991年以来一直担任加利福尼亚州洛杉矶Cedars-Sinai医疗中心预防和康复中心的医疗主任。自2001年起，她还担任斯密特西达斯-西奈心脏研究所芭芭拉史翠珊妇女心脏中心的医学主任和捐赠主席，并担任西达斯-西奈医学中心和加州大学洛杉矶分校戴维格芬医学院的医学教授。从2005年到2009年，她在CV Therapeutics，Inc.的科学顾问委员会任职。她还在非营利委员会、理事会和指导小组中拥有丰富的经验，包括美国心脏病学会、美国心脏协会和美国国家心脏、肺和血液研究所。自2016年以来，Bairey Merz博士一直在多个编辑委员会任职，包括《美国心脏病学会期刊》、《循环》和《欧洲心脏杂志》。Bairey Merz博士拥有芝加哥大学生物科学学士（荣誉）学位和哈佛医学院医学博士（荣誉）学位。她在加州大学旧金山分校完成了内科培训，并在Cedars-Sinai医疗中心完成了心脏病学培训。
Cathleen Noel Bairey Merz,has served as a member of Irhythm Technologies, Inc. Board of Directors since April 2018. Dr. Bairey Merz has been the Medical Director of the Preventive and Rehabilitative Center at the Cedars-Sinai Medical Center in Los Angeles, California, since 1991. She also has been the Medical Director and Endowed Chair of the Barbra Streisand Women's Heart Center at the Smidt Cedars-Sinai Heart Institute since 2001, and a Professor of Medicine at Cedars-Sinai Medical Center and the David Geffen School of Medicine at the University of California at Los Angeles. From 2005 to 2009, she served on the Scientific Advisory Board of CV Therapeutics, Inc. She also has extensive experience on nonprofit boards, councils, and guideline panels ,including the American College of Cardiology, the American Heart Association and the National Heart, Lung, and Blood Institute. Since 2016, Dr. Bairey Merz has been serving on multiple editorial boards, including the Journal of the American College of Cardiology, Circulation, and European Heart Journal. Dr. Bairey Merz holds a B.A. (Honors) in Biological Sciences from the University of Chicago and an M.D. (Honors) from Harvard Medical School. She completed her training in Internal Medicine at the University of California, San Francisco, and Cardiology at Cedars-Sinai Medical Center. - Cathleen Noel Bairey Merz自2018年4月起担任Irhythm Technologies，Inc.董事会成员。Bairey Merz博士自1991年以来一直担任加利福尼亚州洛杉矶Cedars-Sinai医疗中心预防和康复中心的医疗主任。自2001年起，她还担任斯密特西达斯-西奈心脏研究所芭芭拉史翠珊妇女心脏中心的医学主任和捐赠主席，并担任西达斯-西奈医学中心和加州大学洛杉矶分校戴维格芬医学院的医学教授。从2005年到2009年，她在CV Therapeutics，Inc.的科学顾问委员会任职。她还在非营利委员会、理事会和指导小组中拥有丰富的经验，包括美国心脏病学会、美国心脏协会和美国国家心脏、肺和血液研究所。自2016年以来，Bairey Merz博士一直在多个编辑委员会任职，包括《美国心脏病学会期刊》、《循环》和《欧洲心脏杂志》。Bairey Merz博士拥有芝加哥大学生物科学学士（荣誉）学位和哈佛医学院医学博士（荣誉）学位。她在加州大学旧金山分校完成了内科培训，并在Cedars-Sinai医疗中心完成了心脏病学培训。
- Cathleen Noel Bairey Merz,has served as a member of Irhythm Technologies, Inc. Board of Directors since April 2018. Dr. Bairey Merz has been the Medical Director of the Preventive and Rehabilitative Center at the Cedars-Sinai Medical Center in Los Angeles, California, since 1991. She also has been the Medical Director and Endowed Chair of the Barbra Streisand Women's Heart Center at the Smidt Cedars-Sinai Heart Institute since 2001, and a Professor of Medicine at Cedars-Sinai Medical Center and the David Geffen School of Medicine at the University of California at Los Angeles. From 2005 to 2009, she served on the Scientific Advisory Board of CV Therapeutics, Inc. She also has extensive experience on nonprofit boards, councils, and guideline panels ,including the American College of Cardiology, the American Heart Association and the National Heart, Lung, and Blood Institute. Since 2016, Dr. Bairey Merz has been serving on multiple editorial boards, including the Journal of the American College of Cardiology, Circulation, and European Heart Journal. Dr. Bairey Merz holds a B.A. (Honors) in Biological Sciences from the University of Chicago and an M.D. (Honors) from Harvard Medical School. She completed her training in Internal Medicine at the University of California, San Francisco, and Cardiology at Cedars-Sinai Medical Center.
- Karen Ling
-
Karen Ling，最近从美国国际集团（AIG）执行副总裁兼首席人力资源官的职位上退休，她自2019年7月以来一直担任该职位。在此职位上，她负责人力资本管理的各个方面，包括人才获取、培训、发展、薪酬和福利、多样性和包容性。从2014年7月到加入AIG，她曾担任Allergan plc的执行副总裁兼首席人力资源官。这是一家制药公司。在此职位上，她在转型期间制定并监督全球人力资源战略，包括成功启动新的全公司人力资源和文化计划。此前，她曾担任Merck & Co.， Inc.全球人类健康和消费者护理业务的人力资源高级副总裁。在加入默克公司之前，她曾担任先灵葆雅全球薪酬与福利集团副总裁。Ling女士还在Wyeth工作了14年，担任各种职位，负责业务部门的人力资源战略开发，并在Wyeth的劳动和就业部门工作。Ling女士拥有波士顿大学法学院的法学博士学位和耶鲁大学的经济学学士学位。
Karen Ling,recently retired from her role as Executive Vice President and Chief Human Resources Officer for American International Group, Inc. ("AIG"), a position she had held since July 2019. In this role, Ms. Ling oversaw all aspects of human capital management, including talent acquisition, training, development, compensation and benefits, and diversity and inclusion. From July 2014 until joining AIG, Ms. Ling served as Executive Vice President and Chief Human Resources Officer at Allergan plc., a pharmaceutical company. In this capacity, Ms. Ling developed and oversaw a global HR strategy during a period of transition that included successfully launching new company-wide HR resources and cultural initiatives. Previously Ms. Ling was Senior Vice President, Human Resources for Merck & Co., Inc.'s Global Human Health and Consumer Care businesses worldwide. Prior to Merck, she was Group Vice President, Global Compensation & Benefits at Schering-Plough. Ms. Ling also spent 14 years at Wyeth in various positions of increasing responsibility developing HR strategies for business units and working in Wyeth's Labor & Employment Department. Ms. Ling holds a JD from Boston University School of Law and a B.A. in Economics from Yale University. - Karen Ling，最近从美国国际集团（AIG）执行副总裁兼首席人力资源官的职位上退休，她自2019年7月以来一直担任该职位。在此职位上，她负责人力资本管理的各个方面，包括人才获取、培训、发展、薪酬和福利、多样性和包容性。从2014年7月到加入AIG，她曾担任Allergan plc的执行副总裁兼首席人力资源官。这是一家制药公司。在此职位上，她在转型期间制定并监督全球人力资源战略，包括成功启动新的全公司人力资源和文化计划。此前，她曾担任Merck & Co.， Inc.全球人类健康和消费者护理业务的人力资源高级副总裁。在加入默克公司之前，她曾担任先灵葆雅全球薪酬与福利集团副总裁。Ling女士还在Wyeth工作了14年，担任各种职位，负责业务部门的人力资源战略开发，并在Wyeth的劳动和就业部门工作。Ling女士拥有波士顿大学法学院的法学博士学位和耶鲁大学的经济学学士学位。
- Karen Ling,recently retired from her role as Executive Vice President and Chief Human Resources Officer for American International Group, Inc. ("AIG"), a position she had held since July 2019. In this role, Ms. Ling oversaw all aspects of human capital management, including talent acquisition, training, development, compensation and benefits, and diversity and inclusion. From July 2014 until joining AIG, Ms. Ling served as Executive Vice President and Chief Human Resources Officer at Allergan plc., a pharmaceutical company. In this capacity, Ms. Ling developed and oversaw a global HR strategy during a period of transition that included successfully launching new company-wide HR resources and cultural initiatives. Previously Ms. Ling was Senior Vice President, Human Resources for Merck & Co., Inc.'s Global Human Health and Consumer Care businesses worldwide. Prior to Merck, she was Group Vice President, Global Compensation & Benefits at Schering-Plough. Ms. Ling also spent 14 years at Wyeth in various positions of increasing responsibility developing HR strategies for business units and working in Wyeth's Labor & Employment Department. Ms. Ling holds a JD from Boston University School of Law and a B.A. in Economics from Yale University.
- Brian B. Yoor
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Abhijit Y. Talwalkar
-
Abhijit Y. Talwalkar于2005年5月开始担任总裁兼首席执行官，并成为董事会的成员之一。在加入LSI公司之前，自1993年至2005年期间内，他受雇于英特尔公司，英特尔公司是一家微处理器制造公司。在英特尔公司，自1995年至2005年期间内，他出任了一些高级管理职位。他于2011年2月担任LAM研究公司董事会成员。
Abhijit Y. Talwalkar is the former President and Chief Executive Officer of LSI Corporation, a leading provider of silicon, systems and software technologies for the storage and networking markets, a position he held from May 2005 until the completion of LSI's merger with Avago Technologies in May 2014. From 1993 to 2005, Mr. Talwalkar was employed by Intel Corporation, a leading producer of microchips, computing and communications products. At Intel, he held a number of senior management positions, including as Corporate Vice President and Co General Manager of the Digital Enterprise Group, which was comprised of Intel's biness client, server, storage and communications biness, and as Vice President and General Manager for the Intel Enterprise Platform Group, where he foced on developing, marketing, and supporting Intel biness strategies for enterprise computing. Prior to joining Intel, Mr. Talwalkar held senior engineering and marketing positions at Sequent Computer Systems, a multiprocessing computer systems design and manufacturer that later became a part of IBM; Bipolar Integrated Technology, Inc., a very large scale integration (VLSI) bipolar semiconductor company; and Lattice Semiconductor Inc., a service driven developer of programmable design solutions widely ed in semiconductor components.He previoly served as a member of the board of directors of LSI from May 2005 to May 2014 and the U.S. Semiconductor Indtry Association from May 2005 to May 2014. He was additionally a member of the U.S. delegation for World Semiconductor Council proceedings.Mr. Talwalkar earned a B.S. degree in electrical engineering from Oregon State University. - Abhijit Y. Talwalkar于2005年5月开始担任总裁兼首席执行官，并成为董事会的成员之一。在加入LSI公司之前，自1993年至2005年期间内，他受雇于英特尔公司，英特尔公司是一家微处理器制造公司。在英特尔公司，自1995年至2005年期间内，他出任了一些高级管理职位。他于2011年2月担任LAM研究公司董事会成员。
- Abhijit Y. Talwalkar is the former President and Chief Executive Officer of LSI Corporation, a leading provider of silicon, systems and software technologies for the storage and networking markets, a position he held from May 2005 until the completion of LSI's merger with Avago Technologies in May 2014. From 1993 to 2005, Mr. Talwalkar was employed by Intel Corporation, a leading producer of microchips, computing and communications products. At Intel, he held a number of senior management positions, including as Corporate Vice President and Co General Manager of the Digital Enterprise Group, which was comprised of Intel's biness client, server, storage and communications biness, and as Vice President and General Manager for the Intel Enterprise Platform Group, where he foced on developing, marketing, and supporting Intel biness strategies for enterprise computing. Prior to joining Intel, Mr. Talwalkar held senior engineering and marketing positions at Sequent Computer Systems, a multiprocessing computer systems design and manufacturer that later became a part of IBM; Bipolar Integrated Technology, Inc., a very large scale integration (VLSI) bipolar semiconductor company; and Lattice Semiconductor Inc., a service driven developer of programmable design solutions widely ed in semiconductor components.He previoly served as a member of the board of directors of LSI from May 2005 to May 2014 and the U.S. Semiconductor Indtry Association from May 2005 to May 2014. He was additionally a member of the U.S. delegation for World Semiconductor Council proceedings.Mr. Talwalkar earned a B.S. degree in electrical engineering from Oregon State University.
- Bruce G. Bodaken
-
Bruce G. Bodaken ，从2000年至2012年担任Blue Shield of California董事长兼首席执行官。1995年至2000年担任Blue Shield of California总裁兼首席运营官，1994年至1995年担任执行副总裁兼首席运营官。管理式医疗服务提供商F.H.P.，Inc.的高级副总裁兼副首席运营官，1990年至1994年，1980年至1990年在F.H.P。担任多个职位。2013年至2016年担任加州大学公共卫生学院客座讲师，教授医疗保健改革方面的研究生课程。2013年至2015年担任布鲁金斯学会客座学者，专注于基于价值的护理设计。iRhythm Technologies，Inc.董事和薪酬委员会成员，曾任WageWorks，Inc.董事会成员。
Bruce G. Bodaken,Chairman and Chief Executive Officer of Blue Shield of California from 2000 through 2012.President and Chief Operating Officer of Blue Shield of California from 1995 to 2000, and as Executive Vice President and Chief Operating Officer from 1994 to 1995.Senior Vice President and Associate Chief Operating Officer of F.H.P., Inc., a managed care provider, from 1990 to 1994 and held various positions at F.H.P. from 1980 to 1990.Visiting Lecturer at the University of California School of Public Health from 2013 to 2016 teaching graduate courses on health care reform.Visiting Scholar at the Brookings Institute from 2013 to 2015 focused on value-based care design.Director and member of the compensation committee of iRhythm Technologies, Inc. and formerly a member of the board of directors of WageWorks, Inc. - Bruce G. Bodaken ，从2000年至2012年担任Blue Shield of California董事长兼首席执行官。1995年至2000年担任Blue Shield of California总裁兼首席运营官，1994年至1995年担任执行副总裁兼首席运营官。管理式医疗服务提供商F.H.P.，Inc.的高级副总裁兼副首席运营官，1990年至1994年，1980年至1990年在F.H.P。担任多个职位。2013年至2016年担任加州大学公共卫生学院客座讲师，教授医疗保健改革方面的研究生课程。2013年至2015年担任布鲁金斯学会客座学者，专注于基于价值的护理设计。iRhythm Technologies，Inc.董事和薪酬委员会成员，曾任WageWorks，Inc.董事会成员。
- Bruce G. Bodaken,Chairman and Chief Executive Officer of Blue Shield of California from 2000 through 2012.President and Chief Operating Officer of Blue Shield of California from 1995 to 2000, and as Executive Vice President and Chief Operating Officer from 1994 to 1995.Senior Vice President and Associate Chief Operating Officer of F.H.P., Inc., a managed care provider, from 1990 to 1994 and held various positions at F.H.P. from 1980 to 1990.Visiting Lecturer at the University of California School of Public Health from 2013 to 2016 teaching graduate courses on health care reform.Visiting Scholar at the Brookings Institute from 2013 to 2015 focused on value-based care design.Director and member of the compensation committee of iRhythm Technologies, Inc. and formerly a member of the board of directors of WageWorks, Inc.
- Karen McGinnis
-
Karen McGinnis，自2013年6月担任首席财务官。在加入本公司之前，从2009年11月到2013年5月她在半导体设备行业的一家为光刻工具制造商提供光源的全球开发、制造和营销商——Cymer公司的副总裁、财务总监兼首席会计官。McGinnis女士受雇于一家信息技术硬件、软件和服务的全球财富500强的供应商，并从2006年9月到2009年3月担任首席会计官，并从 2001年到2006年9月担任财务高级副总裁。McGinnis女士是一名注册会计师，并获得俄克拉荷马大学（he University of Oklahoma）会计学士学位。
Karen McGinnis has served as a member of board of directors since August 2020. Ms. McGinnis also serves as an Independent Director of Alphatec Holdings, Inc. since June 2019 and of BioSplice Therapeutics, Inc. since March 2021. She was Vice President and Chief Accounting Officer of Illumina, Inc. from November 2017 until her retirement on April 2 2021. Ms. McGinnis served as the Chief Executive Officer and President of Mad Catz Interactive Inc. from February 2016 to March 2017 the Chief Financial Officer of Mad Catz Interactive Inc. from June 2013 to February 2016 and served as the Chief Accounting Officer, Corporate Controller and Vice President of Cymer, Inc. from November 2009 to June 2013. Previously, Ms. McGinnis served as Chief Accounting Officer for Insight Enterprises, Inc. from September 2006 until March 2009 its Senior Vice President of Finance from 2001 through September 2006 and its Vice President of Finance from 2000 through 2001. From 1997 to 2000 she served as the Chief Financial Officer of Horizon. Prior to Horizon, Ms. McGinnis was employed by KPMG LLP from 1989 to 1997 and served as its Senior Assurance Manager. Ms. McGinnis is a Certified Public Accountant and received a bachelor's degree in Accounting from the University of Oklahoma in 1989. - Karen McGinnis，自2013年6月担任首席财务官。在加入本公司之前，从2009年11月到2013年5月她在半导体设备行业的一家为光刻工具制造商提供光源的全球开发、制造和营销商——Cymer公司的副总裁、财务总监兼首席会计官。McGinnis女士受雇于一家信息技术硬件、软件和服务的全球财富500强的供应商，并从2006年9月到2009年3月担任首席会计官，并从 2001年到2006年9月担任财务高级副总裁。McGinnis女士是一名注册会计师，并获得俄克拉荷马大学（he University of Oklahoma）会计学士学位。
- Karen McGinnis has served as a member of board of directors since August 2020. Ms. McGinnis also serves as an Independent Director of Alphatec Holdings, Inc. since June 2019 and of BioSplice Therapeutics, Inc. since March 2021. She was Vice President and Chief Accounting Officer of Illumina, Inc. from November 2017 until her retirement on April 2 2021. Ms. McGinnis served as the Chief Executive Officer and President of Mad Catz Interactive Inc. from February 2016 to March 2017 the Chief Financial Officer of Mad Catz Interactive Inc. from June 2013 to February 2016 and served as the Chief Accounting Officer, Corporate Controller and Vice President of Cymer, Inc. from November 2009 to June 2013. Previously, Ms. McGinnis served as Chief Accounting Officer for Insight Enterprises, Inc. from September 2006 until March 2009 its Senior Vice President of Finance from 2001 through September 2006 and its Vice President of Finance from 2000 through 2001. From 1997 to 2000 she served as the Chief Financial Officer of Horizon. Prior to Horizon, Ms. McGinnis was employed by KPMG LLP from 1989 to 1997 and served as its Senior Assurance Manager. Ms. McGinnis is a Certified Public Accountant and received a bachelor's degree in Accounting from the University of Oklahoma in 1989.
高管简历
中英对照 | 中文 | 英文- Quentin S. Blackford
Quentin S. Blackford担任Dexcom, Inc.的首席运营官，截至2021年3月19日，Blackford先生承担Dexcom, Inc.的战略和企业发展职能，以及Dexcom, Inc.的财务和运营职能。Blackford先生于2017年9月加入Dexcom，担任Dexcom, Inc.的首席财务官，并于2019年10月1日晋升为首席运营官和首席财务官。加入Dexcom之前，他曾担任NuVasive的执行副总裁兼首席财务官（2014年8月至2017年8月）。2016年8月，Blackford先生被提升为执行副总裁、首席财务官、战略和企业诚信主管，负责领导财务、战略、企业发展、合规、质量和监管。从2012年7月到2014年8月，他担任NuVasive的财务和投资者关系执行副总裁，从2011年1月到2012年6月，他担任财务副总裁。他在几次收购中发挥了重要作用，以建立NuVasive的产品组合，进入新的产品领域，以及地理扩张。加入NuVasive之前，Blackford先生曾任职Zimmer Holdings, Inc.，在那里他领导该组织的全球财务规划和分析小组，此外还担任财务总监和牙科部门的财务总监。Blackford先生自2017年10月起担任Alphatec Holdings, Inc.和Axogen, Inc.的董事会独立成员（2019年5月以来）。Blackford先生在Grace College获得会计和工商管理双学士学位后获得了他的注册会计师执照。
Quentin S. Blackford serves as Dexcom, Inc.'s Chief Operating Officer and as of March 19 2021 Mr. Blackford has assumed responsibility for Dexcom, Inc.'s strategy and corporate development functions, in addition to Dexcom, Inc.'s finance and operations functions. Mr. Blackford joined Dexcom in September 2017 as Dexcom, Inc.'s Chief Financial Officer and was also promoted to Chief Operating Officer and Chief Financial Officer, effective October 1 2019. Prior to Dexcom, Mr. Blackford served as NuVasive's Executive Vice President, Chief Financial Officer from August 2014 to August 2017. In August 2016 Mr. Blackford was promoted to the role of Executive Vice President, Chief Financial Officer, Head of Strategy and Corporate Integrity in which role Mr. Blackford was responsible for leading Finance, Strategy, Corporate Development, Compliance, Quality and Regulatory. From July 2012 to August 2014 Mr. Blackford served as NuVasive's Executive Vice President of Finance and Investor Relations, and from January 2011 to June 2012 he served as Vice President, Finance. He was instrumental in several acquisitions to build upon NuVasive's portfolio of products and entry into new product segments, as well as geographic expansion. Prior to his roles at NuVasive, Mr. Blackford worked at Zimmer Holdings, Inc. where he led the organization's Global Financial Planning & Analysis group, in addition to serving as Director of Finance and Controller of the Dental Division. Mr. Blackford has served as an independent member of the Board of Directors of Alphatec Holdings, Inc. since October 2017 and Axogen, Inc. since May 2019. Mr. Blackford obtained his Certified Public Accounting license currently inactive after receiving dual Bachelor of Science degrees in Accounting and Business Administration from Grace College.- Quentin S. Blackford担任Dexcom, Inc.的首席运营官，截至2021年3月19日，Blackford先生承担Dexcom, Inc.的战略和企业发展职能，以及Dexcom, Inc.的财务和运营职能。Blackford先生于2017年9月加入Dexcom，担任Dexcom, Inc.的首席财务官，并于2019年10月1日晋升为首席运营官和首席财务官。加入Dexcom之前，他曾担任NuVasive的执行副总裁兼首席财务官（2014年8月至2017年8月）。2016年8月，Blackford先生被提升为执行副总裁、首席财务官、战略和企业诚信主管，负责领导财务、战略、企业发展、合规、质量和监管。从2012年7月到2014年8月，他担任NuVasive的财务和投资者关系执行副总裁，从2011年1月到2012年6月，他担任财务副总裁。他在几次收购中发挥了重要作用，以建立NuVasive的产品组合，进入新的产品领域，以及地理扩张。加入NuVasive之前，Blackford先生曾任职Zimmer Holdings, Inc.，在那里他领导该组织的全球财务规划和分析小组，此外还担任财务总监和牙科部门的财务总监。Blackford先生自2017年10月起担任Alphatec Holdings, Inc.和Axogen, Inc.的董事会独立成员（2019年5月以来）。Blackford先生在Grace College获得会计和工商管理双学士学位后获得了他的注册会计师执照。
- Quentin S. Blackford serves as Dexcom, Inc.'s Chief Operating Officer and as of March 19 2021 Mr. Blackford has assumed responsibility for Dexcom, Inc.'s strategy and corporate development functions, in addition to Dexcom, Inc.'s finance and operations functions. Mr. Blackford joined Dexcom in September 2017 as Dexcom, Inc.'s Chief Financial Officer and was also promoted to Chief Operating Officer and Chief Financial Officer, effective October 1 2019. Prior to Dexcom, Mr. Blackford served as NuVasive's Executive Vice President, Chief Financial Officer from August 2014 to August 2017. In August 2016 Mr. Blackford was promoted to the role of Executive Vice President, Chief Financial Officer, Head of Strategy and Corporate Integrity in which role Mr. Blackford was responsible for leading Finance, Strategy, Corporate Development, Compliance, Quality and Regulatory. From July 2012 to August 2014 Mr. Blackford served as NuVasive's Executive Vice President of Finance and Investor Relations, and from January 2011 to June 2012 he served as Vice President, Finance. He was instrumental in several acquisitions to build upon NuVasive's portfolio of products and entry into new product segments, as well as geographic expansion. Prior to his roles at NuVasive, Mr. Blackford worked at Zimmer Holdings, Inc. where he led the organization's Global Financial Planning & Analysis group, in addition to serving as Director of Finance and Controller of the Dental Division. Mr. Blackford has served as an independent member of the Board of Directors of Alphatec Holdings, Inc. since October 2017 and Axogen, Inc. since May 2019. Mr. Blackford obtained his Certified Public Accounting license currently inactive after receiving dual Bachelor of Science degrees in Accounting and Business Administration from Grace College.
- Daniel G. Wilson
Daniel G. Wilson，自2019年6月起担任Irhythm Technologies，Inc.战略、企业发展和投资者关系执行副总裁。在此之前，他曾担任Penumbra, Inc.的董事和业务发展主管，该公司是一家专注于创新疗法的全球医疗保健公司。在加入Penumbra之前，他曾在摩根大通担任过10年的多个职位，最近在医疗投资银行部门担任执行董事，专注于数字健康、医疗技术和新兴医疗保健公司。在他职业生涯的早期，他曾在Piper Jaffray的医疗保健投资银行部门担任多个职位。他的职业生涯始于毕马威的审计助理。威尔逊先生拥有加州理工学院州立大学圣路易斯-奥比斯波分校的工商管理学士学位。
Daniel G. Wilson,has served as Irhythm Technologies, Inc. Executive Vice President of Strategy, Corporate Development and Investor Relations since June 2019. Previously, he served as Director and Head of Business Development at Penumbra, Inc., a global healthcare company focused on innovative therapies. Prior to Penumbra, he held various positions at J.P. Morgan over a 10-year tenure, most recently as Executive Director in the Healthcare Investment Banking group focused on digital health, medical technology and emerging healthcare companies. Earlier in his career, he held various positions in Piper Jaffray's Healthcare Investment Banking group. He started his career at KPMG as an Audit Associate. Mr. Wilson has a B.S. in Business Administration from California Polytechnic State University at San Luis Obispo.- Daniel G. Wilson，自2019年6月起担任Irhythm Technologies，Inc.战略、企业发展和投资者关系执行副总裁。在此之前，他曾担任Penumbra, Inc.的董事和业务发展主管，该公司是一家专注于创新疗法的全球医疗保健公司。在加入Penumbra之前，他曾在摩根大通担任过10年的多个职位，最近在医疗投资银行部门担任执行董事，专注于数字健康、医疗技术和新兴医疗保健公司。在他职业生涯的早期，他曾在Piper Jaffray的医疗保健投资银行部门担任多个职位。他的职业生涯始于毕马威的审计助理。威尔逊先生拥有加州理工学院州立大学圣路易斯-奥比斯波分校的工商管理学士学位。
- Daniel G. Wilson,has served as Irhythm Technologies, Inc. Executive Vice President of Strategy, Corporate Development and Investor Relations since June 2019. Previously, he served as Director and Head of Business Development at Penumbra, Inc., a global healthcare company focused on innovative therapies. Prior to Penumbra, he held various positions at J.P. Morgan over a 10-year tenure, most recently as Executive Director in the Healthcare Investment Banking group focused on digital health, medical technology and emerging healthcare companies. Earlier in his career, he held various positions in Piper Jaffray's Healthcare Investment Banking group. He started his career at KPMG as an Audit Associate. Mr. Wilson has a B.S. in Business Administration from California Polytechnic State University at San Luis Obispo.
- Marc Rosenbaum
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Sumi Shrishrimal
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Patrick M. Murphy
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Chad Patterson
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Minang Turakhia
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Mervin Smith
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介